Porton Pharma Solutions, a China-based contract development and manufacturing organization (CDMO), has started construction of a new, state-of-the-art crystallization and drug product facility in Cranbury, NJ. The new building is projected to open in the fourth quarter of 2022. This facility will be cGMP capable for drug product supplies, and will expand the company’s ability to offer integrated drug substance (DS) and drug product (DP) R&D services and early clinical supplies to its client base. The facility will operate under the leadership of Jian Wang, senior vice president of crystallization R&D and drug product within J-Star Research. Porton acquired J-Star back in 2017.

Occupying over 40,000 square feet of space, this $20 million new addition will offer state of the art capabilities, including six cGMP suites for drug product, expanded crystallization R&D and reaction engineering laboratories, offices and supporting utilities. It will host about 70 DS and DP scientists, specializing in various areas such as salt selection, polymorph screening, crystallization process development, particle size engineering, pre-formulation development, preparation of phase 1/2 drug product supplies and DS-DP co-processing.

The facility will be located at 2 Clarke Drive, a few minutes walking distance from the current facility at 6 Cedarbrook Drive in Cranbury, NJ.